Richard Bryce
Chief Medical Officer
Replay available
Rain Enhancement Technologies Holdco, Inc. (RAIN) Q1 2022 Earnings Call
Rain Enhancement Technologies Holdco, Inc. (NASDAQ: RAIN) Q1 2022 earnings conference call, held 2022-05-04. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Sumit Roy
Analyst
Corin Jenkins
Analyst
Bob Doble
Chief Scientific Officer
Avanish Vallanki
Chief Executive Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Rain Enhancement Technologies Holdco, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.069 -- 00:00:04.810 And additional just-in-time sites will be opened as necessary from referrals from the 00:00:04.810 -- 00:00:08.852 Tempus and Carus Genomic Testing Services. 00:00:08.852 -- 00:00:13.893 We anticipate enrolling 65 patients across a range of solid tumors 00:00:13.893 -- 00:00:18.674 and using the same treatment protocol as in the Registrational Mantra Trial. 00:00:18.674 -- 00:00:25.616 That is with melidometan dosed at 260 milligrams in the three out of 14-day schedule. 00:00:25.731 -- 00:00:30.354 We anticipate an early data readout in the fourth quarter of this year and reporting 00:00:30.354 -- 00:00:35.417 patient responses, duration of response, and safety in approximately 10 00:00:35.417 -- 00:00:38.057 evaluable patients. 00:00:38.558 -- 00:00:43.381 Based on the progress made with our Milodermatan clinical program thus far, we're looking 00:00:43.381 -- 00:00:47.464 forward to commencing two additional studies in the fourth quarter of this year. 00:00:47.464 -- 00:00:48.884 As 00:00:48.884 -- 00:00:53.935 Avinash mentioned, we anticipate starting the Mantra 3 study of Milodermatan in 00:00:53.935 -- 00:00:59.099 patients with Merkel cell carcinoma who are resistant or refractory to checkpoint inhibitor 00:00:59.099 -- 00:01:00.640 therapy. 00:01:00.640 -- 00:01:05.473 As a reminder, we believe the majority of patients with Merkel cell carcinoma, up to 00:01:05.473 -- 00:01:10.247 80% of them, have a cancer induced by the polyomavirus, 00:01:10.247 -- 00:01:13.688 which induces MDM2 overexpression. 00:01:13.809 -- 00:01:19.193 We are also encouraged by data from other MDM2 inhibitor programs revealing monotherapy 00:01:19.193 -- 00:01:24.331 activity in the tumor setting. and hence believe that there is an opportunity for an...